PE anti-mouse CD51 104106 from BioLegend

Published Figures

Register or Sign In to View Figures.

Nat Aging
January 01 0001

Fig 1: Circadian 3β-HSD enzymatic activity and age-related decline of its coenzyme NAD+ in the meibomian gland.a, Organotypic eyelid slice from Per2Luc/+ mice and magnified images of PER2::LUC luminescence with Nile red staining. Scale bars, 100 μm. b, Circadian oscillation of PER2::LUC. Arrows indicate representative rhythmic, basal cell layers. Bmal1−/−;Per2Luc/+ eyelid slice failed to keep oscillation. c, Dual immunolabelling of PER2::LUC and Hsd3b6. Arrows indicate representative double-labeled cells. Scale bar, 50 μm. d, Time-of-day-dependent changes in 3β-HSD activity in WT and Bmal1−/− meibomian gland (n = 4 mice per time point). e, Quantification of meibomian gland area in WT (n = 4) and Bmal1−/− (n = 5) mice. *P = 0.0229. f, 24 h mRNA expression of Per2 and Hsd3b6 in laser-microdissected meibomian gland (n = 4 mice per data point). Scale bar, 200 µm. g, 24 h temporal variations in Hsd3b6 protein expression. Immunoreactivities were abolished in Hsd3b6−/− mice. Requirement of NAD+ for dehydrogenase activity of Hsd3b6 (bottom). IB, immunoblot. h, NAD+ levels in the meibomian gland at ZT03 and ZT15. n = 17, ZT03; n = 14, ZT15; biologically independent laser-microdissected tissue samples. *P = 0.0477. i, Meibomian gland NAD+ levels in WT (n = 8) and Bmal1−/− (n = 7) mice. *P = 0.0261. j, Relative mRNA levels of Hsd3b6 in laser-microdissected meibomian gland, normalized to those of Itgav in WT and Bmal1−/− mice. n = 3 mice per group. k, Meibomian NAD+ levels at 8, 14, 20 and 24 mo. n = 8 WT mice per group except n = 7 for 24 mo. *P = 0.0301; **P = 0.0011, versus 14 mo. l, Hsd3b6 mRNA levels at 2–3, 19–20 and 24–25 months of age. n = 8, 2–3 mo; n = 4, 19–20 mo; n = 4, 24–25 mo mouse meibomian glands. Values are presented as mean ± s.e.m. Statistics in k,l were one-way ANOVA and Bonferroni test; statistical test in e,h,i was unpaired, two-sided Student’s t-test. Data presented in a–c,g are representative of four biologically independent experiments with similar results.
Register or Sign In to View Figures.

Journal of experimental & clinical cancer research : CR
July 29 2024

Fig 2: ITGAV is a prognostic biomarker of relapse in cSCC patients beyond current clinical parameters. A and C Representative IF images of (A) Ecad (red)/ Vim (green) and (C) ITGAV (red)/Vim (green)-expressing cells in 3 different NR-PT and Rel-PT samples. Nuclei labelled with DAPI (blue). Scale bar: 100 µM. T: tumor region; S: stroma region. B and D Percentage (mean ± SD) of (B) Ecad+Vim−, Ecad+Vim+, and Ecad−Vim+ and (D) ITGAV− and ITGAV+ cancer cells in NR-PT (n = 11) and Rel-PT (n = 16) samples. Dotted orange line: percentage of ITGAV+ cancer cells above which it could be estimated as a risk factor for cSCC relapse. P-value (unpaired two-tailed Student’s t-test). E Percentage (mean ± SD) of Vim− and Vim+ cancer cells within ITGAV+ cancer cell population in NR-PT (n = 11) and Rel-PT (n = 16) samples. P-value (unpaired two-tailed Student’s t-test). F Comparison of histopathological features of NR-PT and Rel-PT samples. OR: Odds ratio. Ref: reference group for OR. P. ratio: significance of the OR. P. overall: probability of the comparison of means (tumor size and depth) or proportions (histopathological grade and perineural invasion). P-values (unpaired two-tailed Student’s t-test for tumor size and depth, and Fisher’s exact test for histopathological grade and perineural invasion)
Register or Sign In to View Figures.

Journal of experimental & clinical cancer research : CR
July 29 2024

Fig 3: Pharmacological inhibition of IGF1R activity reduces EMP in mixed cSCCs despite not altering tumor growth. A Experimental design for the treatment of mixed cSCCs with vehicle (control) or OSI-906 (IGF1R inhibitor). When the grafted tumors were palpable, mice were treated orally 5 times per week with 30 mg/kg/dose. B Growth kinetics (mean ± SD) of control and OSI-906-treated mixed cSCCs (n ≥ 7/group). P-value (Repeated Measures ANOVA test). C Representative IF images of GFP (green)/pIGF1R (red)/Ep (white)-expressing cells in control and OSI-906-derived cSCCs. Nuclei stained with DAPI (blue). Scale bar: 100 µm. D-F Percentage (mean ± SD) of (D) total GFP+pIGF1R+, (E) epithelial GFP+EpCAM+pIGF1R+, and (F) mesenchymal GFP+EpCAM−pIGF1R+ cancer cells in control (n = 4) and OSI-906 (n = 4) mixed cSCCs. P-value (unpaired two-tailed Student’s t-test). G Percentage (mean ± SD) of EpCAMhigh, EpCAMlow, and EpCAMneg cancer cells generated in control (n = 7) and OSI-906 (n = 8) mixed cSCCs, as determined by flow cytometry analysis. P-value (unpaired two-tailed Student’s t-test). H, I (H) Percentage (mean ± SD) of ITGAV+ cancer cells and (I) median ITGAV intensity (mean ± SD) of cancer cells in control and OSI-906-derived tumors. P-value (unpaired two-tailed Student’s t-test)
Register or Sign In to View Figures.

Journal of experimental & clinical cancer research : CR
July 29 2024

Fig 4: ITGAV abrogation in EpCAMhigh cancer cells reduces the generation of mesenchymal cancer cells in derived tumors. A Demonstration of ITGAV abrogation in EpCAMhigh sh-ITGAV (1 and 2) cancer cells compared with sh-control cancer cells prior to engraftment into immunocompetent syngeneic mice, determined by western blot. Actin was used as a loading control. B Growth kinetics (mean ± SD) of EpCAMhigh sh-control and sh-ITGAV (1 and 2)-derived tumors (n ≥ 12/group). P-value (Repeated Measures ANOVA test). C Representative image of ITGAV expression in the indicated cancer cells after tumor growth. Actin was used as a loading control. D Percentage (mean ± SD) of EpCAMhigh, EpCAMlow, and EpCAMneg cancer cells generated after the engraftment of EpCAMhigh sh-control (n = 16), sh-ITGAV (1) (n = 14), and sh-ITGAV (2) (n = 12) cancer cells into immunocompetent syngeneic mice. P-value (one-way ANOVA with Dunnett’s test). E Western blot image of pSMAD3 induction after TGFβ1 (2.5 ng/µl) treatment for 14 days in the indicated cancer cells. Actin was used as a loading control. F Percentage (mean ± SD) of EpCAMhigh, EpCAMlow, and EpCAMneg cancer cells generated in TGFβ1-treated (+) and untreated (-) EpCAM+ plastic sh-control (n = 2), sh-ITGAV (1) (n = 3), and sh-ITGAV (2) (n = 2) cancer cells. P-value (unpaired two-tailed Student’s t-test)
Register or Sign In to View Figures.

Journal of experimental & clinical cancer research : CR
July 29 2024

Fig 5: pIGF1R promotes EMP acquisition in epithelial cSCC cancer cells. A, B Hierarchical cluster analysis of differentially phosphorylated peptides (FDR p < 0.05) (A) between full epithelial and EpCAM+ plastic cancer cells isolated from WD-SCCs and MD/PD-SCCs, respectively, and (B) between EpCAM+ plastic and EpCAMneg cancer cells isolated from MD/PD-SCCs (n = 3/group). C Venn diagram of the number of proteins specifically phosphorylated in the EpCAM+ plastic signature compared with full epithelial and EpCAMneg cancer cells. D Percentage (mean ± SD) of GFP+pIGF1R+ cancer cells in epithelial (n = 5), mixed (n = 5), and mesenchymal (n = 4) cSCCs, determined by IF assays. P-value (one-way ANOVA with Tukey’s test). E Western blot confirmation of IGF1R knockdown in EpCAMhigh sh-IGF1R (1) cancer cells prior to engraftment into immunocompetent syngeneic mice. Actin was used as a loading control. F Growth kinetics (mean ± SD) of EpCAMhigh sh-control and sh-IGF1R (1)-derived tumors (n ≥ 18/group). P-value (Repeated Measures ANOVA test). G Representative image of IGF1R levels in the indicated cancer cells after tumor growth. Actin was used as a loading control. H Percentage (mean ± SD) of EpCAMhigh, EpCAMlow, and EpCAMneg cancer cells generated after the engraftment of EpCAMhigh sh-control (n = 18) and sh-IGF1R (1) (n = 20) cancer cells into immunocompetent syngeneic mice. P-value (unpaired two-tailed Student’s t-test). I, J (I) Percentage (mean ± SD) of ITGAV+ cancer cells and (J) median ITGAV intensity (mean ± SD) of cancer cells in EpCAMhigh sh-control and sh-IGF1R (1)-derived tumors. P-value (unpaired two-tailed Student’s t-test). K pSMAD3 levels after TGFβ1 (2.5 ng/µl) treatment for 14 days in the indicated cancer cells. Actin was used as a loading control. L Percentage (mean ± SD) of EpCAMhigh, EpCAMlow, and EpCAMneg cancer cells generated in TGFβ1-treated (+) and untreated (-) EpCAM+ plastic sh-control (n = 4) and sh-IGF1R (1) (n = 3) cancer cells. P-value (unpaired two-tailed Student’s t-test). M Median ITGAV intensity (mean ± SD) of sh-control (n = 4) and sh-IGF1R (1) (n = 3) cancer cells treated with TGFβ1 relative to their respective untreated controls. P-value (unpaired two-tailed Student’s t-test)

Be the first to write a review!

Citations:

(44)

Figures:

Supplier Page

Supplier Page from
BioLegend for
PE anti-mouse CD51

BioLegend's PE anti-mouse CD51 is a Rat monoclonal antibody. The PE anti-mouse CD51 Antibody was generated using ITGAV as the antigen. It reacts with Mouse. This antibody has been shown to work in applications such as: Flow Cytometry.

Description

PE anti-mouse CD51 [RMV-7];

Product Specs
ItemPE anti-mouse CD51
CompanyBioLegend
Price $304.00Supplier Page View Company Product Page
Catalog Number104106
NCBI Gene Aliases1110004F14Rik, 2610028E01Rik, CD51, D430040G12Rik
ReactivityMouse
CloneRMV-7
Quantity200 µg
ApplicationsFC - Quality tested
HostRat
Conjugate/TagPE
IsotypeRat IgG1, kappa
Antibody TypePrimary
NCBI Full Gene Nameintegrin alpha V
Concentration0.2mg/ml
FormatPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide
ImmunogenBALB/c mouse IL-2-activated killer (LAK) cells
ClonalityMonoclonal
TargetCD51

Add to Compare List

BioLegend

8999 BioLegend Way

San Diego, California 92121

United States

Phone: 1-877-246-5343 Toll-Free, USA & Canada
1-858-768-5800 International
Fax: 1-877-455-9587

Company Profile

Website: biolegend.com

(1) Megakaryocytes transfer mitochondria to bone marrow mesenchymal stromal cells to lower platelet activationJournal of Clinical InvestigationApril 15, 2025Chengjie Gao, Yitian Dai, Paul A. Spezza, Paul Boasiako, Alice Tang, Giselle Rasquinha, Hui zhong, Bojing Shao, Yunfeng Liu, Patricia A. Shi, et al.157614), Ter119– (Biolegend, catalog 116220), CD31– (Biolegend, catalog 102528), CD51+ (Biolegend, catalog 104106), and PDGFRα+ (Biolegend, catalog 135914). For coculture experiments, murine MSCs were allowed to adhere

(2) An epitranscriptomic program maintains skeletal stem cell quiescence via a METTL3-FEM1B-GLI1 axisThe EMBO JournalFebruary 27, 2025Jing Wang, Weidong Liu, Tiantian Zhang, Manman Cui, Kexin Gao, Pengbo Lu, Shuxin Yao, Ziyan Cao, Yanbing Zheng, Wen Tian, et al.with fluorochrome-conjugated antibodies of PerCP/Cyanine5.5 Streptavidin (405214, BioLegend), CD51-PE (104106, BioLegend), Thy1.1-APC/Cyanine7 (202520, BioLegend), Thy1.2-APC/Cyanine7 (105328, BioLegend), 6C3-PE/Cyanine7

(3) Megakaryocytes transfer mitochondria to bone marrow mesenchymal stromal cells to lower platelet activationJ Clin InvestFebruary 27, 2025Chengjie Gao, Yitian Dai, Paul A. Spezza, Paul Boasiako, Alice Tang, Giselle Rasquinha, Hui Zhong, Bojing Shao, Yunfeng Liu, Patricia A. Shi, et al.157614), Ter119– (Biolegend, catalog 116220), CD31– (Biolegend, catalog 102528), CD51+ (Biolegend, catalog 104106), and PDGFRα+ (Biolegend, catalog 135914). For coculture experiments, murine MSCs were allowed to adhere

(4) IGF1R signaling induces epithelial-mesenchymal plasticity via ITGAV in cutaneous carcinomaJournal of experimental & clinical cancer research : CRJuly 29, 2024Lopez-Cerda M, Lorenzo-Sanz L, da Silva-Diz V, Llop S, Penin RM, Bermejo JO, de Goeij-de Haas R, Piersma SR, Pham TV, Jimenez CR, et al.50–0451-U100), CD49f-FITC 1:10 (GOH3, BD Biosciences, 555735), ITGAV (CD51)-PE 1:150 (RMV-7, BioLegend, 104106), ITGB3 (CD61)-APC 1:150 (2C9.G2, BioLegend, 104316), and VCAM1 (CD106)-APC-eF660 1:150 (429, eBioscience,

(5) Stromal Cell Isolation from Hematopoietic OrgansJournal of Visualized ExperimentsFebruary 12, 2024Trine Kristiansen, Christina Mayerhofer, Karin Gustafsson, David T. ScaddenCD45-PE/Cy7,Biolegend,103114, Rat anti-mouse CD45R/B220-Biotin,Biolegend,103204, Rat anti-mouse CD51-PE,Biolegend,104106, Rat anti-mouse EpCam-BV711,BD Biosciences,563134, Rat anti-mouse Ly-6A/E(Sca-1)-AF700,Biolegend,108142, Rat

(6) Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid LeukemiaJournal of visualized experiments : JoVENovember 10, 2023Kaszuba CM, Rodems BJ, Sharma S, Franco EI, Ashton JM, Calvi LM, Bajaj J.mg/mL Nup98-HoxD13 (NHD13) Mice,Jackson Laboratory,010505, PE anti-mouse CD51 Antibody (RMV-7),Biolegend,104106,0.2 mg/mL PE/Cyanine5 anti-mouse CD140a Antibody (RUO),Biolegend,135920,0.2 mg/mL Penicillin-Streptomycin,Gibco,15140122,"10,000

(7) Enzyme-Cleaved Bone Marrow Transplantation Improves the Engraftment of Bone Marrow Mesenchymal Stem CellsJBMR plusMarch 1, 2023Kawai H, Oo MW, Takabatake K, Tosa I, Soe Y, Eain HS, Sanou S, Fushimi S, Sukegawa S, Nakano K, et al.

(8) Bone Metastasis Initiation Is Coupled with Bone Remodeling through Osteogenic Differentiation of NG2+ CellsCancer discoveryFebruary 6, 2023Zhang W, Xu Z, Hao X, He T, Li J, Shen Y, Liu K, Gao Y, Liu J, Edwards DG, et al.Sca-1-Percp/Cy5.5 (eBioscience, Cat# 45-5981-82, RRID: AB_914372, 0.2mg/ml, 1:200), CD51-PE (BioLegend, Cat# 104106, RRID: AB_2129493, 0.2mg/ml, 1:200), CD140α-PE/Cy7 (BioLegend, Cat# 135912, RRID: AB_2715974, 0.2mg/ml,

(9) Hematopoietic Cell Autonomous Disruption of Hematopoiesis in a Germline Loss-of-function Mouse Model of RUNX1-FPDHemaSphereFebruary 1, 2023Ernst MPT, Pronk E, van Dijk C, van Strien PMH, van Tienhoven TVD, Wevers MJW, Sanders MA, Bindels EMJ, Speck NA, Raaijmakers MHGP.

(10) Resource: A Cellular Developmental Taxonomy of the Bone Marrow Mesenchymal Stem Cell Population in MiceHemaSphereFebruary 1, 2023Pisterzi P, Chen L, van Dijk C, Wevers MJW, Bindels EJM, Raaijmakers MHGP.

(11) A RORγt(+) cell instructs gut microbiota-specific T(reg) cell differentiationNatureOctober 1, 2022Kedmi R, Najar TA, Mesa KR, Grayson A, Kroehling L, Hao Y, Hao S, Pokrovskii M, Xu M, Talbot J, et al.135021, 1:50;CD127 (IL-7Rα) TotalSeq™-A0198 (A7R34), BioLegend 135045, 1:100;CD51 PE (RMV-7), BioLegend 104106, 1:100;CD51 BUV395 (RMV-7), BD 747834, 1:100;CD51 TotalSeq™-A1008 (RMV-7), BioLegend 104111, 1:100;MHCII

(12) B lymphocyte-derived acetylcholine limits steady-state and emergency hematopoiesisNature immunologyApril 1, 2022Schloss MJ, Hulsmans M, Rohde D, Lee IH, Severe N, Foy BH, Pulous FE, Zhang S, Kokkaliaris KD, Frodermann V, et al.BD Biosciences); Sca1-BV421 (108128, clone D7, BioLegend); CD90-BV785 (105331, clone 30-H12, BioLegend); CD51-PE (104106, clone RMV-7, BioLegend); LeptinR-biotin-conjugated (BAF497, clone polyclonal, R&D systems); Streptavidin-BV650

(13) Pancreatic cancer cells render tumor-associated macrophages metabolically reprogrammed by a GARP and DNA methylation-mediated mechanismSignal transduction and targeted therapyOctober 29, 2021Zhang M, Pan X, Fujiwara K, Jurcak N, Muth S, Zhou J, Xiao Q, Li A, Che X, Li Z, et al.

(14) Integrin-α_V-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockadeNature communicationsSeptember 1, 2021Malenica I, Adam J, Corgnac S, Mezquita L, Auclin E, Damei I, Grynszpan L, Gros G, de Montpréville V, Planchard D, et al.suspensions using antibodies specific to the following molecules: CD51 (integrin αV, clone RMV-7, BioLegend 104106, 1/200), E-cadherin (clone DECMA-1, BioLegend 147307, 1/200), H2-Kb/H2-Db (clone 28-8-6, BioLegend 114605,

(15) Decline in IGF1 in the bone marrow microenvironment initiates hematopoietic stem cell agingCell stem cellAugust 5, 2021Young K, Eudy E, Bell R, Loberg MA, Stearns T, Sharma D, Velten L, Haas S, Filippi MD, Trowbridge JJ.

(16) SLPI is a critical mediator that controls PTH-induced bone formationNature communicationsApril 9, 2021Morimoto A, Kikuta J, Nishikawa K, Sudo T, Uenaka M, Furuya M, Hasegawa T, Hashimoto K, Tsukazaki H, Seno S, et al.

(17) Endothelium-derived stromal cells contribute to hematopoietic bone marrow niche formationCell stem cellApril 1, 2021Kenswil KJG, Pisterzi P, Sánchez-Duffhues G, van Dijk C, Lolli A, Knuth C, Vanchin B, Jaramillo AC, Hoogenboezem RM, Sanders MA, et al.

(18) Gut Helicobacter presentation by multiple dendritic cell subsets enables context-specific regulatory T cell generationeLifeFebruary 3, 2021Russler-Germain EV, Yi J, Young S, Nutsch K, Wong HS, Ai TL, Chai JN, Durai V, Kaplan DH, Germain RN, et al.

(19) Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasisNatureJanuary 1, 2021Pastushenko I, Mauri F, Song Y, de Cock F, Meeusen B, Swedlund B, Impens F, Van Haver D, Opitz M, Thery M, et al.used: for use in the system under study (i.e. assay and species). CD51 (rat clone RMV-7, Biolegend Cat#104106, dilution 1:50), BV421-conjugated anti-CD61 (Armenian hamster, clone 2C9.G2, BD Bioscience Cat#553345,

(20) Connective Tissue Growth Factor From Periosteal Tartrate Acid Phosphatase-Positive Monocytes Direct Skeletal Stem Cell Renewal and Fate During Bone HealingFrontiers in cell and developmental biologyJanuary 1, 2021Bai Y, Yu T, Deng J, Yang Y, Tan J, Dai Q, Zhang Z, Dong S, Xu J.

Be the First to Write a Review!

Nat Aging

Journal of experimental & clinical cancer research : CR

Journal of experimental & clinical cancer research : CR

Journal of experimental & clinical cancer research : CR

Journal of experimental & clinical cancer research : CR

PE anti-mouse CD51 from BioLegend

Description

BioLegend

Citations (44)

Reviews

PE anti-mouse CD51 from BioLegend

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map